114 filings
Page 5 of 6
8-K
jptu3gve hnjzib6m1
22 May 19
Regulation FD Disclosure
6:10am
8-K
h1krpnhn3 zoa
20 May 19
Entry into a Material Definitive Agreement
9:28am
8-K
d4cz jfuxuopvz5jafg
20 May 19
BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
9:04am
8-K
ia17xzrqbv mza
7 May 19
BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update
8:17am
8-K
tvomkfxmtxr1b5yv as
1 Apr 19
BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
4:08pm
8-K
wnwuj
25 Mar 19
Other Events
4:45pm
8-K
wyrz h7trmm3hl
12 Mar 19
Other Events
5:21pm
8-K
iio3onbc
11 Mar 19
BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
4:38pm
8-K
oup3if8raqix9
7 Mar 19
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update
4:42pm
8-K
0vd5jwx8mx3i74 cfv
4 Mar 19
Other Events
4:19pm
8-K
ftg4p5keo5xk 2ejza0
11 Feb 19
Regulation FD Disclosure
4:47pm
8-K
a9jz6x33i6hpa w5x
4 Feb 19
Other Events
5:03pm
8-K
gdnhtm
3 Jan 19
Regulation FD Disclosure
4:16pm
8-K
amgabajk26oog80zpgx
27 Dec 18
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation
4:11pm
8-K
wne2l ir84kmfy743
20 Dec 18
BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation
5:08pm
8-K
2v2jhmrt30l5dm4j5p
12 Dec 18
Regulation FD Disclosure
4:11pm
8-K
gaz m49z6
12 Dec 18
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead
9:05am
8-K
n6scw
14 Nov 18
BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development
8:44am
8-K
8y3zfxz0pzfsjc5cgy
9 Nov 18
BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update
7:35am
8-K
gfw5w
5 Nov 18
First-in-human Phase 1b / 2 combination trial of BXCL701 and pembrolizumab (Keytruda®) expected to initiate in 4Q 2018
4:30pm